---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-037467"
form_type: "8-K"
ticker: "MXCT"
cik: "0001287098"
company_name: "MAXCYTE, INC."
filed_at: "2023-03-28T23:59:59+00:00"
generated_at: "2026-06-17T11:53:39.925919+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# MaxCyte names Douglas Swirsky as CFO; salary $425K, option for 350K shares

## Summary
- Douglas J. Swirsky appointed CFO and principal accounting officer, effective March 27, 2023.
- He receives $425K base salary, 45% target bonus, and a nonqualified stock option for 350K shares at $4.11/share.
- Option vests over 4 years: 25% after 12 months, then monthly over 36 months.
- Ron Holtz, who served as interim CFO since April 2022, becomes EVP, Administration.
- Swirsky previously CFO of AavantiBio and CEO of Rexahn and GenVec; chairman of Cellectar Biosciences.

## SEC filing metadata
- accession: 0001104659-23-037467
- form_type: 8-K
- ticker: MXCT
- cik: 0001287098
- company_name: MAXCYTE, INC.
- filed_at: 2023-03-28T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1287098/000110465923037467/0001104659-23-037467-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1287098/000110465923037467/tm2310656d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-037467
- JSON: https://secwatch.observer/filing/0001104659-23-037467.json
- Plain text: https://secwatch.observer/filing/0001104659-23-037467.txt

## Key facts
- Executive change
  Ron Holtz changed role as EVP, Administration at MAXCYTE, INC..
  - Action: continued as
  - Role: EVP, Administration
  source text: Ron Holtz, who had served as the Company’s interim Chief Financial Officer since April 15, 2022, will continue as the Company’s EVP, Administration.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1287098/000110465923037467/0001104659-23-037467-index.htm
- Executive change
  Douglas J. Swirsky was appointed as Chief Financial Officer at MAXCYTE, INC..
  - Action: appointed
  - Role: Chief Financial Officer
  source text: On March 27, 2023, the Board of Directors (the “ Board ”) of MaxCyte, Inc. (the “ Company ”) appointed Douglas J. Swirsky as the Company’s Chief Financial Officer, effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1287098/000110465923037467/0001104659-23-037467-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.